GBL Posts NAV Per Share Of €99.21 As Of End September

NNIT A/S - Q3 2026 REVENUE DKK 409.6M, CONSTANT CURRENCY REVENUE GROWTH -5.9% L impact | EQUITY | Nov 05, 2026, 05:23 PM UTC

REG-NNIT A/S: Performance progressing as planned NNIT A/S: Performance progressing as planned Q3 2026 key highlights NNIT’s financial performance was L impact | EQUITY | Nov 05, 2026, 05:22 PM UTC

Cummins Reports Third-Quarter 2026 Revenue of $9.44B, EPS of $8.25 Cummins said third-quarter sales and earnings increased year over year. Higher sales lifted gross margin, while higher compensation expenses partly offset the gains; the company al M impact | EQUITY | Nov 05, 2026, 05:21 PM UTC

VIRBAC CORPORATION APPOINTS JASON BAILEY AS CFO AND ELIJAH REID AS VP OF HR IN A CONTINUOUS EFFORT TO TRANSFORM THE ORGANIZATION AND ACCELER VIRBAC CORPORATION APPOINTS JASON BAILEY AS CFO AND ELIJAH REID AS VP OF HR IN A CONTINUOUS EFFORT T L impact | EQUITY | Nov 05, 2026, 05:21 PM UTC

EZCORP publishes update to financial calendar EZCORP publishes update to financial calendar EZCORP will release fourth-quarter and full-year f L impact | EQUITY | Nov 05, 2026, 05:21 PM UTC

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to HOUSTON, Nov. 5, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing inn L impact | EQUITY | Nov 05, 2026, 05:20 PM UTC

GBL Posts NAV Per Share Of €99.21 As Of End September

Related stories